Amniotic Fluid Removal during Cell Salvage in the Cesarean Section Patient

Waters, Jonathan H.; Biscotti, Charles V.; Potter, Paul S.; Phillipson, S Eliot

doi:10.1097/00000542-200006000-00008

Cited by 165 publications

(145 citation statements)

References 28 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…This technique involves suctioning of blood from the operative field followed by cell washing, suspension in saline, and reinfusion to the patient [24]. Concerns about its possible association with amniotic fluid embolism (AFE) have made this technique controversial [25][26][27].…”

Section: Intraoperative Cell Salvagementioning

confidence: 99%

“…Fetal squamous cells, meconium, and other particulates have also been implicated in the development of AFE [30]. Waters and colleagues [26] demonstrated that when cells are washed and a leukocyte depletion filter is used, the resulting blood has a concentration of fetal squamous cells similar to a preoperative maternal blood sample [26].…”

Section: Intraoperative Cell Salvagementioning

confidence: 99%

“…Fetal hemoglobin is present in the processed cell saver blood, raising concerns about maternal alloimmunization and the potential for problems with subsequent pregnancies [26,27]. Rh mismatch is particularly important and anti-D immune globulin should be administered to Rh-negative mothers who receive salvaged blood [24].…”

Section: Intraoperative Cell Salvagementioning

confidence: 99%

See 2 more Smart Citations

Blood Component Therapy in Obstetrics

Fuller¹,

Bucklin²

2007

Obstetrics and Gynecology Clinics of North America

View full text Add to dashboard Cite

Section: Intraoperative Cell Salvagementioning

confidence: 99%

Section: Intraoperative Cell Salvagementioning

confidence: 99%

See 1 more Smart Citation

Blood Component Therapy in Obstetrics

Fuller¹,

Bucklin²

2007

Obstetrics and Gynecology Clinics of North America

View full text Add to dashboard Cite

“…Cell salvage has been used in obstetrics to a limited degree because of the fear of amniotic fluid embolism although the exact mechanism is still unclear. In contrast, leukocyte depletion filtering of cell-salvaged blood obtained from cesarean section reduces amniotic fluid components to a concentration equivalent to maternal venous blood (9). This device has been reportedly used safely in !400 cases (4,10).…”

Section: Discussionmentioning

confidence: 99%

A case of placenta percreta with massive hemorrhage during cesarean section

et al. 2014

View full text Add to dashboard Cite

“…Studies examining the quality of blood that would be returned to the mother, if cell salvage had been used at caesarean section, have shown that there is no safety concern with modern equipment as amniotic fluid is both effectively and completely removed by cell salvage processing. 27,28 Despite concerns about AFE as a consequence of cell salvage having proven unfounded in research thus far, 27,28 and evidence that the transfer of amniotic fluid into the maternal circulation is a common event that does not necessarily cause adverse effects, [29][30][31][32] this issue remains of concern to clinicians.…”

Section: Cell Salvage In Caesarean Sectionmentioning

confidence: 99%

A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial

Khan

Moore

Wilson

et al. 2018

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 10/57/32. The contractual start date was in October 2012. The draft report began editorial review in December 2016 and was accepted for publication in March 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by t...

show abstract

Amniotic Fluid Removal during Cell Salvage in the Cesarean Section Patient

Abstract: Leukocyte depletion filtering of cell-salvaged blood obtained from cesarean section significantly reduces particulate contaminants to a concentration equivalent to maternal venous blood.

Cited by 165 publications

References 28 publications

Blood Component Therapy in Obstetrics

Blood Component Therapy in Obstetrics

A case of placenta percreta with massive hemorrhage during cesarean section

A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial

Contact Info

Product

Resources

About